Novartis – Page 2

Novartis Gains World-First Approval of Malaria Treatment for Babies

2 months ago talkbio0Tagged Africa, Approved, artemether-lumefantrine, Coartem, Infant, Infant, Newborn, Malaria, Novartis, Swissmedic, venture

Novartis; malaria; Coartem Baby; Swissmedic; newborns; infants; Africa; approval; artemether-lumefantrine; Medicines for Malaria Venture; not-for-profit

Novartis and ProFound Therapeutics Forge $750M-Per-Target Cardiovascular Pact

3 months ago talkbio0Tagged biobucks, biotech partnership, Cardiovascular Diseases, Drug Discovery, Flagship, Novartis, pharmaceutical milestones, ProFound Therapeutics, Proteomics

Novartis; ProFound Therapeutics; cardiovascular disease; biotech partnership; drug discovery; proteomics; biobucks; flagship pioneering; pharmaceutical milestones

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

3 months ago talkbio0Tagged Arcus Biosciences, Clinical Trials, Gilead, immuno-oncology, iTeos, Merck, Myers, Novartis, Pharma, Roche (company), SmithKline Beecham, squibb, TIGIT gene, Tiragolumab

TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug

Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies

3 months ago talkbio0Tagged Antistreptolysin O, Biogen, Clinical Trials, motor milestones, Nerve Degeneration, Novartis, Pediatric brand name, Phase III, salanersen, Spinal Muscular Atrophy, Spinraza, Zolgensma

Biogen; SMA; Spinraza; salanersen; Phase III; clinical trials; neurodegeneration; motor milestones; pediatric; Novartis Zolgensma; ASO therapy

BMS to close Illinois site as part of cell therapy manufacturing consolidation

4 months ago talkbio0Tagged Acquisition, Cell Therapy, Financial cost, Libertyville Illinois, manufacturing consolidation, Myers, Novartis, squibb, Viral Vector

Bristol Myers Squibb, viral vector production, Libertyville Illinois, manufacturing consolidation, Novartis acquisition, cell therapy, cost cuts

Novartis bolsters renal disease pipeline with $1.7B deal for Regulus

4 months ago talkbio0Tagged farabursen, Goldcrest, Novartis

Goldcrest, farabursen, Novartis

Novartis to buy Regulus Therapeutics for up to $1.7B

4 months ago talkbio0Tagged Acquisition (action), Goldcrest, Kidney Diseases, Novartis

Goldcrest, Novartis, Acquisition (action), Kidney Diseases

Novartis off to “strong” start, prompting guidance raise for 2025

5 months ago talkbio0Tagged guidance raise, Novartis

Novartis, guidance raise

Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations

5 months ago talkbio0Tagged CEOs, EU, Financial cost, Investments, Market, nations, Novartis, Parity, Pharma, Prices, sanofi, Transplant Registry Unified Management Program, U.S.

EU, Novartis, CEOs, Transplant Registry Unified Management Program, Financial cost, Parity, sanofi, Investments, Prices, Pharma, Market, nations, U.S.

Novartis Halts Phase 2 Osteoarthritis Study of ADAMTS-5 Inhibitor Due to Lack of Pain Relief

5 months ago talkbio0Tagged ADAMTS-5, cartilage degradation, Clinical Trial Termination, Degenerative polyarthritis, Drug Development, Inhibitor, Knee pain, M6495, Novartis, Pain, QUC398

Novartis, phase 2 trial, osteoarthritis, knee pain, ADAMTS-5 inhibitor, QUC398, M6495, clinical trial termination, pain relief, cartilage degradation, drug development